Summary
FDA woes are far from over as cited in this article for lupin.
FDA inspection process is a slow one and once trapped in it, it is difficult to get out.
The figures cited are extremly optimistic.
Lupin gets it's 30 - 40 % business from US & this will definately affect in bottom line in the medium term
Analysis
Lupin and other Indian companies have been regularly falling in the US FDA trap for some time now.
Companies line Ranbaxy, Sun etc... have faced similar problems in the past and are yet to completely come out of it.
Lupin is optimisitic which is a good thing, but experience shows its not so easy & not as quick.
In the medium term there will be some pressure on the business from US.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
